SCOPUS 정보 검색 플랫폼

Journal of Medical Case Reports

Volumn 3, Issue , 2009, Pages

Correlations between atazanavir Ctroughand hyperbilirubinemia: A case report

(4) Uglietti, Alessia a Novati, Stefano a Gulminetti, Roberto a Maserati, Renato a

a FONDAZIONE IRCCS POLICLINICO SAN MATTEO (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BILIRUBIN; DIDANOSINE; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ANAMNESIS; ARTICLE; BLOOD ANALYSIS; CASE REPORT; DIARRHEA; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INDUCTION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIPODYSTROPHY; MALE; MEDICAL ERROR; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 72749106635 PISSN: 17521947 EISSN: 17521947 Source Type: Journal
DOI: 10.1186/1752-1947-3-9307 Document Type: Article

Times cited : (8)

References (6)

1
- 27644575794
- Atazanavir: A review of its use in the management of HIV infection
- Atazanavir: a review of its use in the management of HIV infection. T Swainston Harrison LJ Scott, Drugs 2005 65 2309 2336
- (2005) Drugs , vol.65 , pp. 2309-2336
- Swainston Harrison, T.¹ Scott, L.J.²

2
- 33751005307
- Gilbert's disease and atazanavir: From phenotype to UDPglucuronosyltransferase haplotype
- Gilbert's disease and atazanavir: from phenotype to UDPglucuronosyltransferase haplotype. TO Lankisch U Moebius M Wehmeier G Behrens MP Manns RE Schmidt CP Strassburg, Hepatology 2006 44 1324 1332
- (2006) Hepatology , vol.44 , pp. 1324-1332
- Lankisch, T.O.¹ Moebius, U.² Wehmeier, M.³ Behrens, G.⁴ Manns, M.P.⁵ Schmidt, R.E.⁶ Strassburg, C.P.⁷

3
- 75149148053
- Atazanavir Ctrough is associated with efficacy and safety: Definition of therapeutic range
- Boston, Massachusetts. 645
- Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range. D Gonzalez de Requena S Bonora F Canta R Marrone A D'Avolio M Sciandra MG Milia A Di Garbo A Sinicco G Di Perri, 12th Conference on Retroviruses and Opportunistic Infections: 22-25 February 2005 Boston, Massachusetts bstract 645
- 12th Conference on Retroviruses and Opportunistic Infections: 22-25 February 2005
- Gonzalez De Requena, D.¹ Bonora, S.² Canta, F.³ Marrone, R.⁴ D'Avolio, A.⁵ Sciandra, M.⁶ Milia, M.G.⁷ Di Garbo, A.⁸ Sinicco, A.⁹ Di Perri, G.¹⁰

4
- 0037311464
- Methods for integration of pharmacokinetic and phenotypicinformation in the treatment of infection with human immunodeficiency virus
- Methods for integration of pharmacokinetic and phenotypicinformation in the treatment of infection with human immunodeficiency virus. EP Acosta JR King, Clin Infect Dis 2003 36 373 377
- (2003) Clin Infect Dis , vol.36 , pp. 373-377
- Acosta, E.P.¹ King, J.R.²

5
- 24044517189
- Therapeutic drug monitoring of atazanavir: Surveillance of pharmacotherapy in the clinic
- Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. JE Ray D Marriott MT Bloch AJ McLachlan, Br J Clin Pharmacol 2005 60 291 299
- (2005) Br J Clin Pharmacol , vol.60 , pp. 291-299
- Ray, J.E.¹ Marriott, D.² Bloch, M.T.³ McLachlan, A.J.⁴

6
- 33646744190
- 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
- 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. M Johnson B Grinsztejn C Rodriguez J Coco E DeJesus A Lazzarin K Lichtenstein V Wirtz A Rightmire L Odeshoo C McLaren, AIDS 2006 20 711 718
- (2006) AIDS , vol.20 , pp. 711-718
- Johnson, M.¹ Grinsztejn, B.² Rodriguez, C.³ Coco, J.⁴ Dejesus, E.⁵ Lazzarin, A.⁶ Lichtenstein, K.⁷ Wirtz, V.⁸ Rightmire, A.⁹ Odeshoo, L.¹⁰ McLaren, C.¹¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.